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Photodynamic therapy (PDT) is a very promising antineoplastic
treatment, specially for superficial skin tumours, based on the
preferential accumulation of a photosensitizer in malignant tissue
after its administration. Light of an appropriate wavelength illumi-
nation excites the photosensitizer and subsequent photoactivation
results in the release of cytotoxic substances such as singlet
oxygen or free radicals which are responsible for the destruction of
PDT treated tissue (Dougherty et al, 1984). 
At the beginning of the 1990s 5-aminolevulinic acid (ALA), a
precursor of the endogenous photosensitizer protoporphyrin IX
(PpIX), began to be used to induce the selective accumulation of
tetrapyrroles endogenously synthesized in the tumour tissue
(Kennedy and Pottier, 1990; Fukuda et al, 1992). 
ALA-mediated photodynamic therapy (ALA-PDT) shows
promise in skin precancerous stages such as solar keratoses,
Bowen’s disease, and tumours including basal cell carcinomas,
Paget’s disease and squamous cell carcinomas (Kurwa and
Barlow, 1999). Nonmalignant skin pathologies such as psoriasis
(Boehncke et al, 1994) and actinic keratoses, among others, have
also been treated by ALA-PDT (Fritsch et al, 1998). 
However, the fact that ALA is a zwitterion at physiological pH
and therefore has low lipid solubility, limits its clinical application.
ALA poorly passes through biological barriers such as stratum
corneum of the skin and cellular membranes. Hence, ALA-
induced PpIX formation is often restricted to superficial tissue
layers because of both inhomogeneous and partial tissue distribu-
tion in deeper-lying or nodular lesions (Peng et al, 1995). 
It is expected that more lipophilic ALA prodrugs can cross
cellular membranes more easily than ALA. After reaching the site
of action, the prodrug is enzymatically converted to ALA, which
in turn is converted into PpIX. Kloek et al (1996, 1998), Gaullier
et al (1997) and Casas et al (2001) found that long chain ALA
esters are taken up, hydrolysed to the free acid and transformed
into PpIX with higher efficiency than ALA, leading to higher
photosensitiser levels both in vivo and in vitro. 
Some ALA esters have been used in normal mouse skin (Peng
et al, 1996) and in human basal cell carcinomas (Peng et al, 1995),
and a higher and more homogeneous tissue distribution was
produced when compared to that of free ALA-induced porphyrins. 
Van den Akker et al (2000a) using hairless mice showed that
ALA pentyl ester produces only slightly more PpIX than ALA in
UVB-induced (pre)cancerous skin lesions, while in normal skin,
porphyrin levels were equal from both ALA compounds. The
same authors (Van den Akker et al, 2000b), found in normal mice
skin that ALA hexyl ester was not better than ALA in synthesizing
PpIX. In both studies, ALA and ALA esters were delivered in a
cream formulation. 
Another approach aimed at improving the pro-drug skin
penetration is the use of different vehicles and enhancers for their
administration (Casas et al, 1999a, 2000a). 
The aim of this work was to modulate and optimize porphyrin
accumulation and tumoural selectivity, employing different vehi-
cles and the penetration enhancer DMSO, in the delivery of ALA
and ALA hexyl ester using a murine skin tumour model. 
Due to the scarcity of appropriate animal models to study the
effectiveness of ALA-PDT, we employed skin tumours induced
in SENCAR mice by two-stage initiation/promotion protocol.
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Initiation of tumorigenesis by the carcinogen 7,12-dimethyl-
benz[a]anthracene (DMBA), followed by continuous treatment
with phorbol ester promoters, such as 12-o-tetradecanoylphorbol-
13-acetate (TPA), results in the formation of premalignant papil-
lomas (Burns et al, 1983). 
In this paper we have analysed porphyrin formation in chemi-
cally induced squamous papillomas, after topical application of
ALA and He-ALA administered in different formulations, as well
as the pattern of porphyrin distribution in the internal organs, and
the synthesis of porphyrins in distant tumoural and normal skins. 
MATERIALS AND METHODS 
Animals and drugs 
Six- to eight week-old female SENCAR mice were provided by
the Comisión Nacional de Energía Atómica Argentina (CNEA).
Animals were housed separately, acclimatized before use,
subjected to a 12 h light/ 12 h dark cycle and fed with mice chow
(Molinos Rio de la Plata, Argentina), and water ad libitum. 
ALA, 7,12-dimethylbenz[a]anthracene (DMBA) and 12-o-
tetradecanoylphorbol-13-acetate (TPA), were purchased from
SIGMA Chem Co., St Louis, MO, USA. ALA hexyl-ester (He ALA)
was synthesized according to the method previously described by
Casas et al (1999b). All other chemicals were of analytical grade. 
Induction of tumours in SENCAR mice skin 
Chemical carcinogen-induced benign squamous papillomas were
developed employing the following protocol: 6–8-week-old
female SENCAR mice were shaved. Only those animals in
resting phase of the hair cycle were used in the tumour protocol
and treated topically on the dorsal shaved area with a single
topical application of DMBA (20 µ g in 0.2 ml acetone/mouse).
One week later, animals were treated once a week during 4
months with TPA (2 µ g in 0.2 ml acetone/mouse) to obtain papil-
lomas. Using this protocol, after 16 weeks, about 50% of the mice
treated had an average of three to four tumours per mouse. Few
tumours were randomly verified histopatologically as squamous
papillomas. Only animals with closely matched tumour size were
employed. 
Animals were treated in accordance with guidelines established
by the Animal Care and Use Committee of the Argentine
Association of Specialists in Laboratory Animals (AADEALC), in
full accord with the UK Guidelines for the Welfare of Animals in
Experimental Neoplasia (UKCCCR, 1988). 
Preparation and administration of ALA formulation 
Saline solution: the hydrochloric salt of ALA and He-ALA were
dissolved in saline at a concentration of 150 and 225 mg/ml
respectively immediately before use. Saline/ethanol: 40% ethanol
in saline. Saline/DMSO: 10% dimethylsulfoxide in saline. Saline/
DMSO/ethanol: 10% DMSO and 40% ethanol in saline. Cream:
ALA and He-ALA were daily prepared at 20% and 30%, respec-
tively, in an oil in water emulsion cream (Genargen, Argentina). A
total amount of 15 mg ALA and 22.5 mg He-ALA per mouse was
applied in order to obtain an equimolar free ALA concentration for
all formulations. In tumour bearing mice, ALA and He-ALA in
different formulations were topically applied over a single papilloma
surface (weighing approximately 100 mg) plus a 3 mm peritumoural
margin rubbing in the surface during a period of 5 min, time at
which no vestiges of either cream or lotion are visible. Before any
application, mice received mild anaesthesia (Fentanyl and
Diazepam). All formulations were applied under occlusive dress-
ing to avoid distribution of the compounds. 
For porphyrin determinations in both skin and internal organs,
mice having 3–4 papillomas were employed. The peritumoural
skin (3 mm margin of skin surrounding the treated papilloma) was
carefully removed from the tumour itself. The rest of the non-
treated papillomas were pooled for porphyrin extraction. Samples
of distant normal skin were excised from the ventral area of the
mice. 
In experiments aimed at studying porphyrin distribution as a
function of the distance of ALA application, 7–8 tumour-bearing
mice were employed. In this case, a single papilloma was topically
treated as explained above and the distant papillomas were
processed separately for porphyrin measurement. In tumour-free
mice, ALA or He-ALA was applied and rubbed in over an area of
1.76 cm2 in diameter of normal skin, and another three distant
normal skins were excised from different consecutive zones. All
the skins were shaved before processing. 
Optimal time and precursor concentrations were chosen from
previous work (Casas et al, 2000b). 
Tissue porphyrin extraction 
After 3 hr of ALA or He-ALA topical application, animals were
sacrificed. Before killing, mice were injected with heparin (0.15
ml, 1000 UI) and after sacrifice, they were perfused with 200 ml
of sterile saline. The tissue samples were homogenized in a 4:1
solution of ethyl acetate: glacial acetic acid mixture. Blood
samples were heparinized and vigorously vortexed with the same
extraction solvents. The mixtures were centrifuged for 30 min at
3000 g, and the supernatants were added with an equal volume of
5% HCl. Extraction with HCl was repeated until there was no
detectable fluorescence in the organic layer. The aqueous fraction
was used for the determination of porphyrins. For fluorometric
determination, a Shimadzu RF-510 spectrofluorometer was used,
with an emission wavelength of 604 nm and an excitation wave
length of 406 nm, employing a PpIX reference standard.
Statistical analysis 
The unpaired t-test was used to establish the significance of differ-
ences between groups. Differences were considered statistically
significant when P < 0.05. Three mice per group were employed. 
RESULTS 
Figures 1 and 2 show porphyrin synthesis in treated papillomas,
distant papillomas, normal skin surrounding papillomas and
normal distant skin after topical application of ALA and He-ALA
respectively, applied in different formulations. The cream vehicle
is twice as efficient as saline lotion at inducing porphyrin synthesis
in papillomas treated with ALA (Figure 1). However, by adding
ethanol, or DMSO and ethanol to the saline formulation, but not
DMSO alone, tetrapyrrole accumulation can be significatively in-
creased when compared with saline lotion (P = 0.001 and P = 0.0007
respectively). Saline/DMSO/ethanol vehicle induces 3.5 times
more porphyrin accumulation than saline alone. A completely
different pattern is observed in papillomas treated with He-ALA1796 A Casas et al 
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Figure 1 Porphyrin synthesis in skin of tumour-bearing mice after topical application of ALA. Porphyrins were determined 3 h after ALA application in different
vehicles: (   ) control without any treatment, cream ( ), saline lotion ( ), saline/ethanol (  ), saline/DMSO ( ) and saline/DMSO/ethanol ( ). Bars represent
porphyrin values (mean ± SD)
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Figure 2 Porphyrin synthesis in skin of tumour-bearing mice after topical application of He-ALA. Porphyrins were determined 3 h after He-ALA application in
different vehicles: (   ) control without any treatment, cream ( ), saline lotion ( ), saline/ethanol (  ), saline/DMSO ( ) and saline/DMSO/ethanol ( ). Bars
represent porphyrin values (mean ± SD) Hexyl ALA in the photodynamic treatment of skin induced tumours 1797
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(Figure 2), where cream is the best vehicle, inducing 3.5 times
more porphyrins than saline lotion; addition of DMSO to saline
He-ALA can increase porphyrin synthesis by a factor of 1.5. 
The amount of porphyrins in distant papillomas is similar to that
found in ALA-applied papillomas, independently on the vehicle,
except for the saline/DMSO/ethanol formulation, inducing a
significant lower tetrapyrrole accumulation in the distant tumour
(P = 0.03). When using He-ALA formulations, porphyrin concen-
trations measured in distant papillomas, except for saline lotion, in
all other vehicles are half the amount synthesized in He-ALA
treated papillomas. 
In general, peritumoural skins surrounding papillomas, which
were also treated with ALA or the ALA ester, exhibit porphyrin
levels similar to those found in ALA and He-ALA treated papil-
lomas. The notorious exception is the peritumoural skin treated
with ALA in saline/ethanol/DMSO, which accumulated half the
amount of tumoural porphyrins. 
In distant normal skin tissue of mice treated with ALA or He-
ALA, porphyrin levels are lower than those of treated tumors,
but treated papilloma to distant normal skin ratios depend on
the vehicle employed, and in general they are much higher for 
He-ALA formulations (Table 1). The use of cream as a vehicle
for both ALA and He-ALA, induces higher ratios. However, in
the case of He-ALA, but not ALA, when either ethanol or DMSO
are added to the saline formulation, the ratios are largely increased. 
Figures 3 and 4 show porphyrin accumulation in internal organs
after topical application of papillomas with ALA and He-ALA
respectively. As a general pattern for all vehicles, porphyrin accumu-
lation in liver, kidney, spleen and blood is higher in tumour-bearing
mice topically treated with ALA as compared with the He-ALA-
treated mice, and the factor of increase depends on the tissue. 
In Figure 5 we demonstrate that porphyrins formed from ALA
saline lotion in normal skin of a non-tumour bearing mice, do not
depend on the distance from the point of application, and there is
no selectivity for the site of application. The use of the cream
vehicle for ALA application induces a more confined porphyrin
accumulation in the site of application, although in the ventral side
of the animal (75 mm distance), porphyrin concentration is not
different from that formed in the treated zone. In He-ALA-treated
skin, both saline and cream induce an accumulation of porphyrins
strongly dependent on the distance from the site of application,
and it is the cream vehicle the one inducing lower porphyrin accu-
mulation in distant skins. 
In Figure 6 it is shown that after application of ALA lotion to a
single papilloma, porphyrins are uniformly distributed to all distant
papillomas, whereas He-ALA induces a higher concentration in the
Table 1 Papilloma to normal distant skin porphyrin ratios. Porphyrins were
determined 3 h after application of ALA or He-ALA to a single papilloma in
different vehicles. Papilloma/ normal skin porphyrin ratios were calculated
with data from Figures 1 and 2 
ALA ratio He-ALA ratio 
Controla 0.6 0.6 
Cream 3.2 9.6 
Saline lotion 1.3 4.9 
Saline/ethanol 1.2 7.2 
Saline/DMSO 1.1 9.9 
Saline/DMSO/ethanol 2.1 8.1
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Figure 3 Porphyrin synthesis in tissues of tumour-bearing mice after topical application of ALA. Porphyrins were determined 3 h after ALA application in
different vehicles: (   ) control without any treatment, cream ( ), saline lotion ( ), saline/ethanol (  ), saline/DMSO ( ) and saline/DMSO/ethanol ( ). Bars
represent porphyrin values (mean ± SD) expressed in µ g/g tissue and µ g/ml blood 1798 A Casas et al 
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treated papilloma and porphyrin accumulation in the non-treated
tumours decreases with the distance from the He-ALA applied
papilloma. 
DISCUSSION 
From these results, we can conclude that similar porphyrin
concentrations can be reached in the skin tumours employing
either ALA or He-ALA delivered in their optimal formulations
employing equimolar amounts of the prodrugs. A lotion formula-
tion containing DMSO and ethanol is the best vehicle for topical
ALA delivery to papillomas, whereas cream is the most efficient
formulation for He-ALA application. However, the use of cream
as a vehicle of both ALA and He-ALA, induces the highest
porphyrin tumour/normal skin ratios. As a consequence, the
cream vehicle should be the election for the treatment of skin
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Figure 4 Porphyrin synthesis in tissues of tumour-bearing mice after topical application of He-ALA. Porphyrins were determined 3 h after He-ALA application
in different vehicles: (   ) control without any treatment, cream ( ), saline lotion ( ), saline/ethanol (  ), saline/DMSO ( ), and saline/DMSO/ethanol ( ). Bars
represent porphyrin values (mean ± SD) expressed in µ g/g tissue and µ g/ml blood 
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Figure 5 Distribution pattern of normal skin porphyrins from non-tumour
bearing mice after ALA and He-ALA application in a normal skin area.
Porphyrins were measured 3 h after application of ALA saline lotion (  ), 
He-ALA saline lotion (   ), ALA cream (  ) He-ALA cream (   ) 
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Figure 6 Distribution pattern of papilloma porphyrins from tumour bearing
mice after ALA and He-ALA application in a single papilloma. Porphyrins
were measured 3 h after ALA (  ) or He-ALA (   ) saline lotion topical
application Hexyl ALA in the photodynamic treatment of skin induced tumours 1799
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malignancies with He-ALA. In the case of ALA, although
saline/ethanol/DMSO induces higher porphyrin tumour levels, the
use of cream should also be recommended when higher selectivity
is needed. 
Some vehicles induce differential porphyrin accumulation. For
example, saline/ethanol/DMSO as the ALA vehicle induces a
surprisingly low porphyrin accumulation in distant papillomas as
well as in peritumoural skin as compared to porphyrin levels accu-
mulated in the treated tumours. In addition, He-ALA applied as
saline lotion induces higher porphyrin values in distant papillomas
when comparing with the treated to distant papillomas ratios for
the other vehicles. 
In general, a similar amount of porphyrins is synthesized in
distant papillomas from ALA when compared with ALA-applied
papillomas, demonstrating that either ALA itself and/or the
porphyrins formed by synthesis can be distributed throughout the
vasculature and accumulate in distant tumours. On the other hand,
lower porphyrin synthesis occurs in distant papillomas from He-
ALA treated papillomas, showing that He-ALA and/or porphyrins
formed from the precursor, are more selectively localized in the
site of application. 
Looking at tissues far from the site of application, distant
normal skin porphyrin levels are lower than porphyrin levels in
distant papilloma tissues, showing that porphyrins accumulate
preferentially in tumour than in normal skin, even though either
ALA or He-ALA were applied in remote zones. 
Peritumoural skins surrounding papillomas, which were also
treated with the porphyrin precursors, exhibit porphyrin levels
similar to those found in both ALA and He-ALA treated papil-
lomas. This demonstrates that when either ALA or its derivative is
applied on tumoural or normal skin, the induced porphyrin
synthesis is the same, and that special care must be taken to
restraining ALA application to the affected skin. 
In addition to the selectivity of prophyrin accumulation from
He-ALA showed in skin tissues, the amount of tetrapyrroles accu-
mulated in internal organs is much lower in mice treated with He-
ALA than in those treated with ALA. Even comparing ALA in
saline/DMSO/ethanol with He-ALA in cream, the best vehicle for
each compound, porphyrin synthesis in liver and blood is four
times lower in the former demonstrating that, independently on the
vehicle, the use of ALA hexyl ester provides a clear advantage in
selective porphyrin accumulation. 
Peng et al (1996) applied ALA and other ALA esters (methyl,
ethyl and propyl) to normal mouse skin and detected tissue
fluorescence by means of an optical-based point monitoring
system in situ. They found no porphyrins in areas other than that in
which the ALA ester cream was applied, while in the case of
ALA, a significant fluorescence was seen in the skin outside the
application area. In our work, employing porphyrin extraction
procedures, fluorescence values in distant skins as well as in
internal organs were also much lower for He-ALA than ALA-
treated mice, although in both cases they were much higher than
basal levels. 
The confinement to the site of application achieved by the use
of ALA hexyl ester demonstrates that ALA, and not porphyrin, is
the main molecule likely to be distributed through the blood-
stream. Topically applied He-ALA may be retained by stratum
corneum, which may act as a reservoir (Rougier and Lotte,
1986), and diffuse superficially, leading to the pattern of skin
porphyrin accumulation dependant on the distance of applica-
tion. 
In this regard, Van den Akker et al (2000b) demonstrated that
the stratum corneum was the main barrier for He-ALA penetra-
tion. They found that the ester of ALA did not induce higher PpIX
production in normal mouse skin compared to ALA. Employing a
cream formulation and tape stripping of the stratum corneum they
demonstrated that this was the layer limiting and lowering PpIX
production. 
The same group (Van den Akker et al, 2000a) employed a
shorter ester of ALA, the ALA pentyl ester, and found higher PpIX
levels in the stratum corneum of lesional UVB-exposed mouse
skin, but not in the dysplastic layer of the epidermis, showing that
this ester also poorly diffusses as compared with ALA. 
In our work, porphyrin accumulation in internal organs after
topical He-ALA application to papillomas, shows that the hexyl
ester of ALA does reach the dermis. Moreover, after applying He-
ALA in normal skin of non-tumour bearing mice, we also found
the same pattern formed in internal organs for porphyrin accumu-
lation. Our procedure of applying the creams and lotions by
rubbing in the surface during 5 min, both in lesional and normal
skin, may be facilitating the passage of the ALA ester to deeper
layers. Different procedures of ALA application avoiding the
rubbing in of the creams and lotions are currently under investiga-
tion. 
An additional explanation to the confinement of He-ALA is that
the intracellular conversion of the ester to free ALA in the actual
site of application may be preventing the efflux of the hydrolysed
ALA to the bloodstream to reach non-tumour tissues. 
The confinement of porphyrins and, very likely of the He-ALA,
implies the avoidance of potential unwanted side effects. In the
case of topical use of ALA to discrete lesions, although skin
photosensitivity and liver porphyrin accumulation have not proved
to be a clinical problem, the confinement of He-ALA itself to the
site of application would be preventing any possible normal tissue
cytotoxicity. Although the toxicological profile of He-ALA is
poorly characterized at present, we have reported dark cytotoxicity
after exposure of a tumour cell line to concentrations of He-ALA
as high as 1.4 mM (Casas et al, 2001). Moreover, another future
clinical applications of ALA-PDT requiring larger amounts of pro-
photosensitizer, such as the treatment of early stage cutaneous
T-cell lymphomas and breast secondaries in the chest wall would
also be expected to profit from the benefits of porphyrin restraint. 
We conclude that, by varying the vehicle composition it is
possible to obtain similar porphyrin levels employing either ALA
or its hexyl ester derivative. We wish to emphasize that He-ALA
has the additional advantage of confining porphyrin synthesis to
the site of its topical application, either on the tumour or on normal
skin, more efficiently than ALA. 
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